Abstract
Oncotype Dx is a genetic test that has been incorporated into the 2017 AJCC breast cancer staging system for ER positive, HER2-negative, lymph node-negative patients to predict the risk of recurrence. Recent data suggest that immunohistochemistry (ER, PR, HER2, and Ki-67) and histologic subtype may identify patients that will not benefit from Oncotype Dx testing. A total of 371 patients underwent Oncotype Dx testing at our institution from 2012 to 2016. Oncotype recurrence score was categorized as low- (ORS = 0-10), intermediate- (11-25), or high risk (26-100). Invasive carcinomas were categorized based on histologic subtype as "favorable" (mucinous, tubular, cribriform, tubulolobular, and lobular) and "unfavorable" (ductal, mixed ductal and lobular, and micropapillary carcinoma). All cases were estrogen receptor positive and HER2-negative. Clinical and histologic predictors of low-risk ORS were assessed in univariate and multivariate logistic regression. A total of 371 patients were categorized by ORS as low risk (n = 85, 22.9%), intermediate risk (n = 244, 65.8%), and high risk (n = 42, 11.3%). The histologic subtypes with the highest percentage of high-risk ORS were invasive micropapillary (n = 4/17, 23.5%), pleomorphic lobu...Continue Reading
References
Dec 14, 2004·The New England Journal of Medicine·Soonmyung PaikNorman Wolmark
Dec 7, 2005·International Journal of Cancer. Journal International Du Cancer·Christian RuizGuido Sauter
Jan 13, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eleftherios P MamounasNorman Wolmark
Mar 4, 2011·Breast Cancer Research and Treatment·K H AllisonA M Gown
Jun 29, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Oct 6, 2011·British Journal of Cancer·S SahebjamL C Panasci
Oct 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jack CuzickJohn F Forbes
Sep 1, 2010·Experimental and Therapeutic Medicine·Reiki NishimuraNobuyuki Arima
Oct 9, 2013·Archives of Pathology & Laboratory Medicine·Antonio C WolffUNKNOWN College of American Pathologists
Mar 22, 2015·The Oncologist·Xavier PivotChristian Villanueva
May 2, 2015·Current Treatment Options in Oncology·Erin F Cobain, Daniel F Hayes
May 2, 2015·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Bradley M TurnerDavid G Hicks
Jul 16, 2015·PloS One·Rumiko TashimaNobuyuki Arima
Aug 15, 2015·The Breast Journal·Niamh ConlonLee K Tan
Sep 20, 2015·Clinical Breast Cancer·Michaela L TsaiKaren K Swenson
Sep 29, 2015·The New England Journal of Medicine·Joseph A SparanoGeorge W Sledge
Dec 1, 2015·Archives of Pathology & Laboratory Medicine·Philip E BomeislHannah L Gilmore
Jan 26, 2016·Applied Immunohistochemistry & Molecular Morphology : AIMM·Thaer KhouryMateusz Opyrchal
Jan 26, 2016·Hematology/oncology and Stem Cell Therapy·Lubna N ChaudharyChristopher R Chitambar
Jun 26, 2017·Breast Cancer Research and Treatment·Scott KizyJane Yuet Ching Hui
Citations
Jul 3, 2019·NPJ Breast Cancer·Amy E McCart ReedPeter T Simpson
Jun 27, 2019·Biomarkers in Medicine·San-Gang WuZhen-Yu He
Jan 1, 2020·Scientific Reports·Verena SchildgenOliver Schildgen
Jan 9, 2021·Breast Cancer Research : BCR·Amy E McCart ReedSunil R Lakhani
Mar 7, 2021·Journal of Personalized Medicine·Azzurra IrelliMassimo De Martinis
Mar 13, 2021·The Breast Journal·Matthew G DaveyMichael J Kerin